For people with malignant pleural mesothelioma (MPM),

I have more living to do

Optune Lua is the first FDA-approved treatment*
for MPM in over 15 years. Learn more

Optune Lua in addition to chemotherapy is approved to treat people with unresectable, locally advanced or metastatic, malignant pleural mesothelioma.
To find out what these words mean, click here

A clinical study showed that using Optune Lua
in addition to chemotherapy provided

Learn more about study results for Optune Lua™ + chemo

*FDA approved under the Humanitarian Device Exemption pathway.

In a clinical study, Optune Lua was used with chemotherapy (pemetrexed and platinum-based chemotherapy) in 80 untreated patients with unresectable (unable to be removed via surgery) malignant pleural mesothelioma.

Pemetrexed and platinum-based chemotherapy.

  • Optune Lua is not a medicine and does not enter the bloodstream
    • When used with chemotherapy, the most common device-related side effect was skin irritation
  • In the clinical study, the only side effect related to Optune Lua use was skin irritation seen in 71% of people (66% mild-to-moderate and 5% severe)
    • Most skin irritation is reversible and can be treated with topical ointments, creams, or solutions prescribed by your doctor
View study results

Designed for your everyday life

Optune Lua is wearable and portable–so continuous treatment with TTFields can be received almost anywhere.

See how Optune Lua can fit in your life
Designed with your lifestyle in mind

More than 18,000 people around the world have started Optune®, a cancer treatment that works the same way as Optune Lua

More than 15,000 patients have been treated with TTFields

Optune has been used since 2011 to treat a type of brain cancer called glioblastoma, also known as GBM.

The FDA first approved Optune to treat adults with recurrent GBM in 2011. In 2015, the FDA approved Optune + chemotherapy (Temozolomide, also known as Temodar®) for adults with newly diagnosed GBM.

Optune Lua for MPM was classified as a Humanitarian Use Device (HUD), approved under the Humanitarian Device Exemption (HDE) pathway.

Optune for GBM was approved under the Premarket Approval (PMA) pathway.

nCompassTM brochure

nCompass offers 24/7 support for you and your caregiver.

nCompass™offers 24/7 support for you and your caregiver. Learn more

Need help talking to your doctor?

Download a guide to help you talk to your doctor about whether Optune Lua is right for you.

Download resources can help answer some additional questions you have about Optune Lua™. Download here
Next: Disease overview
What is the Optune Lua™ approved to treat?
jump to isi

Optune Lua is a wearable, portable, FDA-approved device indicated for…

Leaving OptuneLua.com

Novocure® does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.